Rasmus HolmJorgensen - Acrivon Therapeutics, Chief Officer
| ACRV Stock | 7.52 0.17 2.31% |
Insider
Rasmus HolmJorgensen is Chief Officer of Acrivon Therapeutics, Common
| Age | 52 |
| Address | 480 Arsenal Way, Watertown, MA, United States, 02472 |
| Phone | 617 207 8979 |
| Web | https://www.acrivon.com |
Rasmus HolmJorgensen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Rasmus HolmJorgensen against Acrivon Therapeutics, stock is an integral part of due diligence when investing in Acrivon Therapeutics,. Rasmus HolmJorgensen insider activity provides valuable insight into whether Acrivon Therapeutics, is net buyers or sellers over its current business cycle. Note, Acrivon Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Acrivon Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Rasmus HolmJorgensen over a year ago Payment of 1470 shares by Rasmus HolmJorgensen of Acrivon Therapeutics subject to Rule 16b-3 |
Acrivon Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2441) % which means that it has lost $0.2441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3778) %, meaning that it created substantial loss on money invested by shareholders. Acrivon Therapeutics,'s management efficiency ratios could be used to measure how well Acrivon Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. Net Tangible Assets is likely to climb to about 205.8 M in 2024, whereas Total Assets are likely to drop slightly above 117.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Carl Langren | Lumos Pharma | 69 | |
| Ronald CPA | RenovoRx | N/A | |
| Anne Moon | Tempest Therapeutics | N/A | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Ramtin MD | RenovoRx | 58 | |
| James JD | Eliem Therapeutics | 58 | |
| James Ahlers | RenovoRx | 60 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Lisa Miller | Lumos Pharma | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Angela Nelms | RenovoRx | 47 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| MBA MD | Ikena Oncology | 59 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| David MBA | Seres Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 |
Acrivon Therapeutics, Leadership Team
Elected by the shareholders, the Acrivon Therapeutics,'s board of directors comprises two types of representatives: Acrivon Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acrivon. The board's role is to monitor Acrivon Therapeutics,'s management team and ensure that shareholders' interests are well served. Acrivon Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acrivon Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter MD, Chairman, CoFounder | ||
| Jesper Olsen, Head CoFounder | ||
| Dr MBA, Senior Affairs | ||
| Katharine CPA, Vice Accounting | ||
| Bruce Close, Vice Compliance | ||
| MaryAlice JD, Chief Officer | ||
| Crystal Mercado, Global HR | ||
| Kristina Masson, Exec CoFounder | ||
| Parvin Miah, VP Resources | ||
| Rasmus HolmJorgensen, Chief Officer | ||
| Kristina MBA, Executive CoFounder | ||
| Eric Devroe, Chief Officer | ||
| Erick MD, Chief Officer |
Acrivon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acrivon Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 50.7 M | ||||
| Shares Outstanding | 31.14 M | ||||
| Shares Owned By Insiders | 22.38 % | ||||
| Shares Owned By Institutions | 75.97 % | ||||
| Number Of Shares Shorted | 1.11 M | ||||
| Price To Book | 1.19 X | ||||
| EBITDA | (59.85 M) | ||||
| Net Income | (60.39 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.